Praxismed Advances Access to Transcranial Magnetic Stimulation (TMS) for Depression and Mental Health Care Through Philippine Psychiatric Association Engagement

Manila, Philippines – Praxismed Technologies Inc., a Philippine-based distributor of advanced medical equipment, announced its participation in the 52nd Annual Convention of the Philippine Psychiatric Association (PPA), marking the company’s formal engagement with the country’s leading professional organization for psychiatry. Through this milestone, Praxismed reinforced its commitment to advancing mental health care by supporting wider access to Neurosoft’s Transcranial Magnetic Stimulation (TMS)—a non-invasive, evidence-based treatment option for depression.

Held from January 20 to 23, 2026, at Crowne Plaza Manila Galleria, the PPA Annual Convention brought together psychiatrists, mental health professionals, and key stakeholders under the theme “Empowering, Uniting and Healing: Our Collective Journey Towards National Well-Being.” Praxismed’s participation highlighted the role of innovation and collaboration in addressing the country’s growing mental health needs.

TMS is a US FDA-cleared, non-invasive brain stimulation therapy for Major Depressive Disorder (MDD), including patients who have not achieved adequate response to antidepressant medications. By delivering targeted magnetic stimulation to specific brain regions involved in mood regulation, TMS offers a non-pharmacologic option that may be used as an alternative or adjunct to existing treatment approaches, as determined by the attending clinician.

Interest in TMS has continued to grow globally following research developments from Stanford University, particularly studies on accelerated TMS approaches such as the SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) protocol. While conducted under controlled research settings, the encouraging outcomes reported in these studies have drawn significant attention from medical experts and researchers worldwide, highlighting the evolving potential of neuromodulation in psychiatric care.

Through its partnerships with international technology providers, Praxismed has helped make FDA-cleared Neurosoft’s TMS systems available in several major hospitals and institutions in the Philippines, including the National Center for Mental Health (NCMH) and Rizal Medical Center (RMC). With TMS now accessible locally, Filipino patients have additional, evidence-based options for managing depression—expanding care pathways beyond medication alone.

“Joining the Philippine Psychiatric Association allows us to engage more closely with the psychiatric community in advancing patient-centered mental health solutions,” said Charmaine Lou German, President and Chief Executive Officer of Praxismed Technologies Inc. “By helping make FDA-cleared TMS available in major hospitals, we support clinicians in offering scientifically validated, non-invasive treatment options to patients who may not have benefited from conventional therapies.”

During the convention, Praxismed engaged psychiatrists and mental health professionals in discussions on the responsible integration of neuromodulation technologies into clinical practice, emphasizing evidence-based use, appropriate patient selection, and alignment with existing standards of care.

Praxismed’s participation in the PPA Convention underscores its broader mission of elevating healthcare standards through innovation, education, and long-term partnerships—guided by its core philosophy, Driven by Knowledge, Defined by Service. As awareness and acceptance of modern mental health treatments continue to grow, the company remains committed to working alongside clinicians and institutions to help ensure that effective, evidence-based care is within reach for Filipinos.

This press release has also been published on VRITIMES